At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
PF-04620110 +2 moredrug
Likely dose
PF-04620110 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Efficacy And Safety Of 4-Week Administration Of Multiple Oral Doses Of PF-04620110 In Type 2 Diabetes Mellitus Subjects With Insufficient Glycemic Control On Metformin
In Brief
A Phase 1 clinical trial evaluating PF-04620110 and Placebo for Type 2 Diabetes Patients. Completed, enrolled 48 participants across 3 sites.
Detailed Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Patients
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionMay 2011
TodayJul 2026
First PostedFeb 17, 2011
Enrollment StartFeb 1, 2011
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.4 years ago
Interventions
PF-04620110drug
5 mg of PF-04620110 given once daily
PF-04620110drug
2.5 mg of PF-04620110 given twice daily
Placebodrug
Matching placebo giving for 4 weeks